Search

In countries of Western Europe and the United States, prostate cancer (PC) is the most diagnosed cancer nonepitelial of man, representing 25% of cases of cancer diagnosed "de novo" in men and 9% of the cases of death by cancer. Introduction of prostatic specific antigen (PSA) as a method of screening, in 1988, changed radically the epidemiology of CP by progressive increase in the number of cases of CP diagnosed in "early stages". European Randomised Study of Screening for Prostate Cancer (ERSPC) has been found to decrease by about 20% of mortality due to CP using PSA as a screening test to 162 000 men asymptomatic with ages ranging between 55 and 69 years. In the Clinic of Urology Clinical Hospital "Prof. Dr. Th. Burghele", the incidence of CP compared to other cancers places it in second place after bladder cancer and before renal malignant tumors. The principal means of diagnosis of CP are: rectal examination, the level of prostatic specific antigen seric, transrectal echography and prostate biopsy. [ABSTRACT FROM AUTHOR]